IMNM
Immunome Inc.Company Information
- Company Name
- Immunome Inc.
- CIK
- CIK0001472012
- Category
- Non-accelerated filer
- Ticker: Exchange
- IMNM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IMNM
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-05
- Last sale
- 2026-09-11
- Shares purchased (TTM)
- 110,468
- Shares sold (TTM)
- 914,448
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 97,308,458
- Shares outstanding
- 113,272,931
- Ownership
- 85.91%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 1.94%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 218 | 583 | 653 | 273 | 144 | 258 | 143 | 156 | 165 | 270 | 99 | 91 | ||||||
| Available For Sale Securities Debt Securities Current | 302 | - | 0 | 0 | 124 | 60 | 74 | 85 | 113 | 40 | 39 | - | ||||||
| Prepaid Expense And Other Assets Current | 18 | 12 | 7 | 7 | 9 | 6 | 4 | 4 | 6 | 4 | 7 | 1 | ||||||
| Assets Current | 538 | 594 | 661 | 280 | 277 | 323 | 221 | 244 | 284 | 313 | 145 | 91 | ||||||
| Property Plant And Equipment Net | 17 | 17 | 15 | 12 | 11 | 11 | 10 | 7 | 6 | 4 | 2 | 1 | ||||||
| Operating Lease Right Of Use Asset | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 2 | 3 | 1 | 2 | 0 | ||||||
| Deferred Costs | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 0 | - | ||||||
| Assets | 565 | 620 | 683 | 299 | 296 | 343 | 240 | 257 | 296 | 320 | 149 | 93 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 6 | 3 | 6 | 5 | 9 | 14 | 4 | 7 | 7 | 3 | 3 | ||||||
| Accrued Liabilities And Other Liabilities | 30 | 22 | 42 | 25 | 18 | 18 | 33 | 26 | 20 | 11 | 8 | 3 | ||||||
| Contract With Customer Liability Current | - | - | 0 | 0 | 0 | 4 | 7 | 10 | 13 | 13 | 10 | 17 | ||||||
| Liabilities Current | 36 | 27 | 45 | 31 | 23 | 31 | 54 | 40 | 40 | 31 | 22 | 23 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | 2 | 5 | 3 | ||||||
| Operating Lease Liability Noncurrent | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 2 | 2 | 1 | 1 | - | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 1 | 0 | ||||||
| Liabilities | 40 | 31 | 49 | 35 | 27 | 36 | 59 | 42 | 42 | 34 | 29 | 87 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,381 | 1,371 | 1,362 | 922 | 870 | 865 | 697 | 650 | 642 | 638 | 343 | 136 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | - | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Retained Earnings Accumulated Deficit | -855 | -782 | -728 | -658 | -601 | -557 | -516 | -436 | -388 | -352 | -223 | -130 | ||||||
| Stockholders Equity | 525 | 589 | 634 | 264 | 269 | 307 | 181 | 215 | 254 | 286 | 120 | 6 | ||||||
| Liabilities And Stockholders Equity | 565 | 620 | 683 | 299 | 296 | 343 | 240 | 257 | 296 | 320 | 149 | 93 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 200 | ||||||
| Common Stock Shares Issued | 113 | 113 | 113 | 92 | 87 | 87 | 64 | 60 | 60 | 60 | 43 | 12 | ||||||
| Shares Outstanding | 113 | 113 | 113 | 92 | 87 | 87 | 64 | 60 | 60 | 60 | 43 | 12 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialImmunome Inc. (IMNM) — SEC Financial Statements & Analysis
Immunome Inc. (IMNM) is a pharmaceutical preparations company, incorporated in DE. Immunome Inc. trades on Nasdaq as: IMNM. Immunome Inc. (IMNM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Immunome Inc. carries a market cap of $2.40B, a P/E ratio of -9.44x, a P/B ratio of 4.57x, a P/S ratio of 616.26x, an enterprise value of $2.18B, and an EV/EBITDA multiple of -8.15x. On profitability, it posts an operating margin of -5947.90%, a net margin of -5593.85%, a Return on Equity (ROE) of -64.03%, a Return on Assets (ROA) of -59.03%, and a Return on Invested Capital (ROIC) of -125.04%. Per share, it reports EPS of $-2.25, diluted EPS of $-2.25, free cash flow per share of $-1.93, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 19.75% year-over-year, and EPS growth of -8.02% year-over-year. On the balance sheet, it maintains a current ratio of 15.08x, a quick ratio of 14.56x, working capital of $502.74M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, an interest coverage ratio of -16.76x, free cash flow of $-219.09M (TTM), and net debt of $-217.92M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.40B
- P/E TTM
- -9.44x
- EPS TTM
- $-2.25
- P/B TTM
- 4.57x
- ROE TTM
- -64.03%
- ROA TTM
- -59.03%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-219.09M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Immunome Inc. in?
Immunome Inc. (IMNM) operates in the Pharmaceutical Preparations industry.
What exchange does IMNM trade on?
Immunome Inc. (IMNM) trades on the Nasdaq.
Where is Immunome Inc. incorporated?
Immunome Inc. is incorporated in DE.
When was Immunome Inc. (IMNM)'s most recent SEC filing?
Immunome Inc. (IMNM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is IMNM's market cap?
Immunome Inc. (IMNM) has a market capitalization of $2.40B as of 2026-06-30.
What is IMNM's EPS (earnings per share)?
Immunome Inc. (IMNM)'s trailing twelve month EPS is $-2.25 as of 2026-06-30.
What is IMNM's ROE (return on equity)?
Immunome Inc. (IMNM)'s trailing twelve month Return on Equity (ROE) is -64.03% as of 2026-06-30.
What is IMNM's ROA (return on assets)?
Immunome Inc. (IMNM)'s trailing twelve month Return on Assets (ROA) is -59.03% as of 2026-06-30.
What is IMNM's ROIC (return on invested capital)?
Immunome Inc. (IMNM)'s trailing twelve month Return on Invested Capital (ROIC) is -125.04% as of 2026-06-30.
What is IMNM's EV/EBITDA?
Immunome Inc. (IMNM)'s trailing twelve month EV/EBITDA is -8.15x as of 2026-06-30.